ExactCure

ExactCure, founded in 2017 and headquartered in France, is pioneering the field of personalized medicine with its innovative eHealth software solution. The company's slogan, "Our Digital Twin simulates the concentration of drugs in the blood of patients, based on their personal characteristics," succinctly captures its mission to customize drug therapies.

With its Digital Twin technology, ExactCure addresses the significant global challenge of inappropriate medical treatments, which cause over 1 million deaths and incur $1 trillion in healthcare costs annually. By considering individual characteristics like gender, age, and weight, the Digital Twin provides real-time predictions of drug efficacy and interactions, thereby improving patient safety and reducing iatrogenic side effects.

The solution is delivered via a patient app and a SaaS dashboard for healthcare providers. ExactCure received its last investment from EIT Digital on 01 January 2022 through a Support Program, indicating ongoing investor interest in its transformative potential. The company's presence in the Biotechnology, Health Care, and Mobile industries positions it well for future growth and impact.